Quick summary
Thymus Extract (Thymostimulin) is a mixture of thymic polypeptides from calf thymus that stimulates T-cell differentiation. Investigated for immune support in cancer and surgical patients, though interest has shifted to isolated thymic peptides.
Overview
Thymus Extract (Thymostimulin) is a partially purified preparation of thymic polypeptides derived from calf thymus tissue, first developed in Italy in 1976. It contains a heterogeneous mixture of peptides with molecular weights ranging from 1 to 12 kDa that stimulate T-cell differentiation and maturation. It has been investigated for immune support in cancer patients, surgical patients, and those with chronic infections.
Mechanism of action
Thymus Extract contains a complex mixture of thymic hormones and peptides including thymosin fractions, thymulin-like peptides, and other thymic factors that collectively regulate T-lymphocyte development and immune homeostasis. These peptides stimulate T-cell differentiation and maturation in the thymus, regulate natural killer (NK) cell activity, modulate dendritic cell function, and induce the release of pro-inflammatory cytokines in appropriate contexts. By restoring thymic output of mature T-lymphocytes, thymic extracts are proposed to compensate for age-related thymic involution and the progressive immunosenescence that accompanies it. Individual peptide fractions within the extract include precursors to thymosin alpha-1, thymopoietin, and thymulin, though the exact composition varies between preparations and batches due to biological variation in the extraction process.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| immune support research | intramuscular | 25–150 mg | twice weekly for 4–6 weeks | European clinical trial protocols used 25–150 mg IM doses. Exact dosing varies by preparation batch standardization. |
| subcutaneous research use | subcutaneous | 10–50 mg | twice to three times weekly | Subcutaneous dosing used in some protocols; concentration and bioavailability varies by preparation. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Thymostimulin has been studied in clinical trials for reducing infections in surgical patients, supporting immune function in cancer patients undergoing chemotherapy, and treating chronic or recurrent infections. Initial evidence suggests reduced infection incidence in at-risk patient populations. A 1991 BioDrugs review summarized evidence from European clinical trials showing T-cell reconstitution and reduced infection rates. No large, modern Phase 3 RCTs have been completed meeting contemporary standards. Thymus Extract preparations lack standardization by active components, making cross-study comparison difficult. Interest has shifted toward isolated thymic peptides (thymosin alpha-1, thymalin) with defined compositions.[1][2][3][4]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Thymus Extract for synergistic effects.
Legal status
Not FDA-approved as a pharmaceutical. Thymostimulin was investigated in Europe and the US but never received FDA NDA approval. Thymosin alpha-1 (a defined component) is separately approved in some countries. Available in Western markets as a research substance or supplement. Not for therapeutic human use.
Sourcing & access
Research compound
Thymus Extract is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
Thymus Extract, also known as Thymostimulin, is a heterogeneous mixture of thymic polypeptides (1-12 kDa) derived from calf thymus tissue. It contains precursors to thymosin alpha-1, thymopoietin, and thymulin, and was first developed in Italy in 1976 for immune support research.
The extract contains multiple thymic hormones and peptides that collectively regulate T-lymphocyte development and immune homeostasis. These peptides stimulate T-cell differentiation, regulate natural killer cell activity, modulate dendritic cell function, and aim to compensate for age-related thymic involution and immunosenescence.
No, Thymus Extract is not FDA-approved as a pharmaceutical. It was investigated in Europe and the US but never received NDA approval. It is available as a research substance only and is not for therapeutic human use.
Reported side effects in clinical use include injection site pain, rare anaphylaxis, transient fever, and fatigue. The long-term safety profile is poorly characterized because preparation composition varies between manufacturing batches due to biological variation in calf thymus source material and extraction methods. This standardization gap is one reason research interest has shifted toward defined thymic peptides like thymosin alpha-1.
Thymus Extract preparations lack standardization by active components, making cross-study comparison difficult. Research interest has shifted toward isolated thymic peptides like thymosin alpha-1 and thymalin, which have defined compositions and more reproducible effects.
Research references
- Thymic peptides and immune reconstitution: clinical use in immunodeficiencyPubMed
- Thymosin fraction 5 and thymic peptide extracts in cellular immunity restorationPubMed
- Thymus extracts and immunosenescence: restoring T-cell function in agingPubMed
- Thymic humoral factor and thymosin in clinical immunologyPubMed